Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 29 | 2026Merck and Dexcom Q3 ’26 Earnings; Ascletis Ph2 T2DM Oral GLP-1RA Data; Oura Ring Obesity StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 29 | 2026Lilly Raises Guidance (again) Amidst “The Largest New Category Expansion in the History of the Pharmaceutical Industry;” Lilly Q3 ’26 earningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i, Topics Oct 28 | 2026BI Creates Metabolic Health Steering Committee; Reta Tops Ozempic; Lilly Initiates Elora CV Safety Study; Dexcom to Launch G7 15 Day in Canada; Viking and Beta Bionics Q3 ’26 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 27 | 2026Novartis and Wave Q3 ’26 Earnings; Hengrui Business Updates; Novo/Lilly DTC Ad Lawsuit; EVP and President of Lilly International to RetirePurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 26 | 2026Regeneron Ph3 Olatorepatide Obesity Study; Senseonics FIH Freedom Study; Corxel Goes Public; Awiqli Pediatric FDA ApprovalPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, Topics Oct 23 | 2026Potential New Brand Name for Cagrisema?; New Novo T2DM Asset; Zenagamtide Ph3 AMBITION 4 Registered; Tidepool Receives Grant Next-gen AlgorithmPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 23 | 2026Roche Q3 ’26 Earnings; Rezera Files for IPO; Fractyl Restructuring; BI Partners with Microsoft; Lilly Ph2 oral GGG Obesity Study; AbbVie Lutikizumab Data and ABBV-295 CombinationPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 21 | 2026Lilly Publishes TRIUMPH-1 and TRIUMPH-2 OSA Results; Abbott Q3 ’26 Earnings; Novo Wegovy Pill France Launch; ADA CSO/CMO TransitionPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 20 | 2026Novo REDEFINE 1 Post Hoc Analyses; Ascletis Preclinical QW Oral Peptide Data; Pfizer Berobenatide OSA Study; AZ/Oracle AI Partnership; Lilly/METiS LNP-Delivery Technology PartnershipPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 19 | 2026Merck Acquires Silence; Sanofi Insulin Manufacturing Expansion; Lilly Ph3 EloraTZP Pivotal Studies; Cytokinetics Myqorzo Health Canada ApprovalPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Oct 16 | 2026October CHMP Agenda Highlights; Pfizer Initiates Q3M Berobenatide Study; Novo Licenses New Drug Discovery Platform; Fractyl Shares 6-Month Revita Procedure Results; FDA Reaffirms Reta’s Classificaiton as a Drug; MiniMed Appoints Board; Sequel twiist AID Insulin-Treated T2DM FDA ClearancePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Oct 15 | 2026Novartis Terminates Ph3 Pelacarsen Studies; AZ Partners with insitro; Dexcom Publishes CONNECT RCT Results; Pfizer China-Based QM Berobenatide Obesity Study; Modular Medical Digital Learning Tool; Medtronic Finalizes MiniMed Separation; Atrogi Oral GRK2-Biased ß2-Adrenergic Modulator DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 14 | 2026Verdiva Terminates Weekly Oral GLP-1RA Maintenance Study; Two Deaths Linked to Black Market Reta; Zealand Partners with Generate; Ultragenyx Sells Two PRVs; Amgen At-Home Autoinjector MariTide Study; iBio Preclinical Activin E Data; Biomea FIH BMF-650 Data; Caspian Menin Inhibitor Development StrategyPurchase Blast
$599
Posted in: Allogeneic, Other, Topics Oct 13 | 2026Rona Partners with Roche for ALK7-Targeting Asset; MetaVia Appoints New CMO; SAB-142 FDA Fast Track DesignationPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Oct 12 | 2026Insulet Omnipod Discover Launch; October CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 09 | 2026Amgen T2DM Ph3 MariTide H2H vs. Sema Study; Oral VK2735 Ph3 Obesity Program; Ascensia Enters Another CGM PartnershipPurchase Blast
$599
Posted in: Glucose Monitoring, Other, Topics Oct 08 | 2026MiniMed Initiates 16-day CGM Study; FDA Accepts Bayer’s Finerenone Non-T2DM CKD sNDA; Ribo Life Science Submits Ph1 Application for INHBE siRNA Obesity Study in EUPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 07 | 2026Ph2 ARO-INHBE MASH Study; Arrowhead Plozasiran for sHTG in STAR Program; ZUPREME-2 Topline Data; Zealand New SVP BD; Esperion and Renata Generic BA Agreement; Ozari Offers Compounded TirzepatidePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Oct 07 | 2026EASD 2026 Winners/Not Winners Analysis: Who Came Out on Top… and Who Didn’t?Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Oct 06 | 2026Viking Initiates Oral VK2735 Maintenance Study and the CCO Shares DeparturePurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
